← Back to patent-cliff list
Elinzanetant
Tier C — Watch / tradeElinzanetant
GSK
Originator
2025
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：NK1R, NK3R
Brand：Lynkuet
Indications (approved)：Hot flushes, Vasomotor symptoms
Regional status
US
Approved
2025-10-24
EU
Approved
2025-07-10
China
Phase I
2022-05-23
Japan
Phase I
2021-08-11
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Elinzanetant?
Approved indications include: Hot flushes, Vasomotor symptoms.
When does the Elinzanetant patent expire?
No public expiry year is available for Elinzanetant yet; this page updates once verified.
How do I get a quote for Elinzanetant intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01